Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

FDA Approves Pegfilgrastim to Protect Against Chemotherapy-Related Neutropenia

March 1, 2002
Publication
Article
OncologyONCOLOGY Vol 16 No 3
Volume 16
Issue 3

The US Food and Drug Administration has approved Amgen’s pegfilgrastim (Neulasta) for use in decreasing the incidence of infection, as manifested by febrile neutropenia. The agent, administered in a single fixed dose per chemotherapy cycle, is indicated for patients with nonmyeloid malignancies who are receiving myelosuppressive chemotherapy associated with a significant incidence of febrile neutropenia.

The US Food and Drug Administration hasapproved Amgen’s pegfilgrastim (Neulasta) for use in decreasing the incidenceof infection, as manifested by febrile neutropenia. The agent, administered in asingle fixed dose per chemotherapy cycle, is indicated for patients withnonmyeloid malignancies who are receiving myelosuppressive chemotherapyassociated with a significant incidence of febrile neutropenia.

Nearly 50% of cancer chemotherapy patients develop severeneutropenia, and, on average, less than 10% receive proactive protection fromneutropenia. Studies have shown that 30% to 40% of patients who receive certaintypes of chemotherapy and are not given a white blood cell booster willexperience neutropenia with fever.

Less Frequent Dosing

Until now, granulocyte colony-stimulating factor (G-CSF,filgrastim, [Neupogen]) was the only agent shown to decrease the risk ofinfection and hospitalization as a result of chemotherapy-induced neutropenia.However, the burden of frequent daily dosing (for as many as 14 consecutivedays) led many health-care professionals to delay intervention with filgrastimuntil after a neutropenic infection developed.

"The less frequent dosing of Neulasta means thatpatients will require fewer painful injections, fewer office visits for thoseinjections, and fewer disruptions to their lives at a time when they areoverwhelmed with a serious disease," said Frankie Ann Holmes, md, a leadclinical trial investigator and associate director of research at US Oncology inHouston. "This approval means that hundreds of thousands of chemotherapypatients at risk for infection may now receive Neulasta as protection at theonset of each treatment cycle before complications arise."

Proven in Clinical Trials

Data from two pivotal phase III studies in breast cancerpatients (310 receiving a 100-µg/kg dose, 157 receiving a fixed 6-mg dose)demonstrated that a single dose of pegfilgrastim provided protection frominfection comparable to a mean of 11 daily injections of standard G-CSF (5µg/kg/d). The randomized, double-blind trials were conducted in breast cancerpatients undergoing as many as four cycles of chemotherapy with doxorubicin anddocetaxel (Taxotere).

Days of severe neutropenia were comparable between treatmentgroups in all cycles. The mean duration of severe neutropenia in cycle 1appeared to be equivalent for patients in the pegfilgrastim and filgrastimgroups: an average of 1.8 vs 1.6 days, respectively, in the fixed-dose trial,and 1.7 vs 1.6 days in the by-weight dosing trial. The average weight ofpatients was 160 lb (72.4 kg), with more than 76% weighing 154 lb (70 kg)or more. Pegfilgrastim was comparable to filgrastim with respect to rates offebrile neutropenia across all chemotherapy cycles in both studies.

Data from phase II studies in patients with variousmalignancies receiving a variety of chemotherapy regimens further supported thesafety and efficacy of pegfilgrastim. These studies in patients with breastcancer, thoracic tumors (including lung cancer), non-Hodgkin’s lymphoma, andHodgkin’s disease demonstrated that the efficacy of a single injection ofpegfilgrastim (100 µg/kg) was similar to that of daily injections offilgrastim (5 µg/kg/d).

Safety Tested

Pegfilgrastim was found to be safe and well-tolerated. In clinical trials,the most common adverse event following combination chemotherapy in 465 patientswith lymphoma and solid tumors was bone pain, which was reported in 26% ofpatients. In most cases, the bone pain was controlled with nonnarcoticanalgesics. The most serious adverse event was low oxygen in the blood, reportedin one patient. In addition, although not reported in patients receivingpegfilgrastim, rare events of respiratory distress syndrome, splenic rupture,and sickle cell crisis occurred in patients receiving the parent compound,filgrastim.

Articles in this issue

Single-Agent Rituximab in Early-Stage Chronic Lymphocytic Leukemia
Recruitment for Trial of Adjuvant Trastuzumab Under Way
Tolerance of Treatment Subsequent to Front-Line Tositumomab/Iodine-131 Tositumomab in Patients With Follicular Lymphoma
Successful Treatment of Pure Red Cell Aplasia With Rituximab in Patients With Chronic Lymphocytic Leukemia
Rituximab in the Treatment of Acquired Factor VIII Inhibitors
A Phase II Study of Apolizumab, a Humanized Monoclonal Antibody, in Patients With Relapsed or Refractory Follicular, Small Lymphocytic, or Marginal Zone/MALT B-Cell Lymphoma
Support for New Medicare Pay Formula
Phase II Trial of CHOP Followed by Rituximab, a Chimeric Monoclonal Anti-CD20 Antibody, for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma: SWOG 9800
A Randomized Trial of Fludarabine and Mitoxantrone Plus Rituximab vs CHOP Plus Rituximab as First-Line Treatment in Patients With Follicular Lymphoma
Irinotecan-Containing Regimen Improves Survival in Small-Cell Lung Cancer
Subsequent Chemotherapy Regimens Well Tolerated After Radioimmunotherapy With Ibritumomab Tiuxetan for Non-Hodgkin’s Lymphoma
Treatment of Acquired Factor VIII Deficiency With Rituximab
Phase III Trial of Virulizin for Advanced Pancreatic Cancer
Phase II Study of Subcutaneous Alemtuzumab (Campath) Therapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Rituximab Treatment in Patients With Immune Thrombocytopenic Purpura
Recent Videos
Acupuncture
Related Content
Advertisement

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.


48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
May 25th 2025
Article

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article
Related Content
Advertisement

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.


48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
May 25th 2025
Article

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.